← ANALYST RATINGS · TIPRANKS
Diamedica Therapeutics (DMAC): analyst forecast and price target
Analyst consensus
Moderate Buy1 Buy0 Hold0 Sell
Ratings of 1 analysts in the last 3 months12-month forecast
Based on 1 price targets given in the last 3 months, the average target is $12.00, the highest $12.00, the lowest $12.00. The average is +58.5% from the last price of $7.57.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | −0.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Hold | −0.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | −0.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.50−6.2% | Hold | −0.9% | Reiterated | 17.10.26on TipRanks 00:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $8.00 → $7.50−6.2% | Hold | −0.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.50−6.2% | Hold | −0.9% | Reiterated | 15.10.26on TipRanks 00:05 | — | |
| Matthew Caufield★★★★★★★★★★#1718 · hits 42% · avg +10.1% | H.C. Wainwright | $12.00 | Buy | +58.5% | Reiterated | 21.09.26on TipRanks Sep 22 05:45 | +4.4%next day +7.2% · 5 days +15.6% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | — | Buy | — | Reiterated | 24.06.26on TipRanks Jun 25 06:31 | +1.3%next day −3.4% · 5 days +15.3% | ↗ |
| Thomas Flaten★★★★★★★★★★#1650 · hits 47% · avg +8.9% | Lake Street | $14.00 | Buy | +84.9% | Reiterated | 23.06.26on TipRanks 09:08 | +8.1%next day +1.3% · 5 days +10.3% | ↗ |
| Joshua Schimmer★★★★★★★★★★#407 · hits 51% · avg +19.0% | Cantor Fitzgerald | $25.00 | Buy | +230.3% | Reiterated | 21.01.26on TipRanks Jan 22 07:20 | +6.3%next day +4.0% · 5 days +4.4% | ↗ |
| Stacy Ku★★★★★★★★★★#2387 · hits 50% · avg +9.3% | TD Cowen | — | Buy | — | Initiated | 30.10.25on TipRanks 05:50 | +5.7%next day +0.5% · 5 days −9.7% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Diamedica Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.00 at a price of $8.27 (+45.1%); now: $12.00 at $7.57 (+58.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 3 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.21 (from $-0.23 to $-0.19). Last quarter: $-0.19.
Best top-analyst consensus in the sector · Healthcare
About Diamedica Therapeutics
- CEO: Dietrich John Pauls
- Employees: 35
- Two Carlson Parkway, Minneapolis, MN, 55305, US
- www.diamedica.com
DiaMedica Therapeutics Inc. operates as a clinical-stage biopharmaceutical entity dedicated to advancing therapeutic solutions for neurological and renal disorders. Its primary drug candidate, DM199, a recombinant human tissue kallikrein-1 protein, is currently undergoing a Phase 2 REDUX trial to assess its efficacy in treating moderate to severe chronic kidney disease linked to Type 1 or Type 2 diabetes. Furthermore, DM199 is being evaluated in Phase 2/3 REMEDY2 trials for acute ischemic stroke patients. In addition to DM199, the company is also developing DM300, which is in its pre-clinical stage for the treatment of various inflammatory conditions. Founded in 2000 and headquartered in Minneapolis, Minnesota, the company was previously known as DiaMedica Inc. before adopting its current name, DiaMedica Therapeutics Inc., in December 2016.
Data from the stock’s TipRanks forecast page, read 145 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗